Axoft, a neurotechnology company building implantable Brain-Computer Interfaces, has raised an oversubscribed $55 million Series A to expand its clinical trials globally and progress U.S. regulatory approval of its iBCI platform, bringing its total funding to more than $60 million. The round was led by C.P. Group Innovation, with participation from Alumni Ventures, the Stanford President’s Venture Fund, Hillhouse Investment, and Gaorong Ventures.
The Cambridge, Massachusetts-based company’s iBCIs are built using its proprietary Fleuron material, which is up to 10,000x softer than the polyimide used in existing brain implants, delivering superior biocompatibility, reduced tissue scarring, and improved neural data stability over time. The material also provides 8x more region access and 32x more sensors per thread than standard flexible probes. Since its 2022 seed round, Axoft has completed first-in-human clinical trials in more than 11 patients worldwide, with research published in Nature in December 2023 and June 2025. Clinical collaborations are underway with Mass General Brigham, and the company recently completed a first-in-human study with The Panama Clinic involving four patients undergoing brain tumor resection.
The new capital will also be used to build a good manufacturing practice facility for mass production of its iBCIs, expand its software engineering, microfabrication, and chemistry teams, and support a recently opened subsidiary in Grenoble, France.
KEY QUOTE:
At Axoft, the neural data quality we unlock doesn’t just make iBCIs more effective, it opens the door to minimally invasive surgery, allows access to deeper brain regions and enables the next generation of AI-driven real-time decoding. Better neural signals are the foundation everything else is built on. This new funding and strategic support from C.P. Group Innovation allows us to expand our work into global markets.
Dr. Paul Le Floch, Co-Founder and CEO, Axoft
